UBS Group’s First Trust Indxx Medical Devices ETF MDEV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$394 Hold
19
– – ﹤0.01% 10661
2026
Q2
$364 Buy
19
+10
+111% +$189 ﹤0.01% 9894
2026
Q1
$171 Buy
+9
New +$184 ﹤0.01% 10055
2025
Q2
– Sell
-790
Closed -$15.9K – 10613
2025
Q1
$15.9K Buy
790
+130
+20% +$2.74K ﹤0.01% 8374
2024
Q4
$13.6K Sell
660
-126
-16% -$2.7K ﹤0.01% 8135
2024
Q3
$17.5K Buy
786
+723
+1,148% +$15.1K ﹤0.01% 7446
2024
Q2
$1.25K Sell
63
-32
-34% -$654 ﹤0.01% 8614
2024
Q1
$2.03K Buy
+95
New +$1.96K ﹤0.01% 7992
2023
Q4
– Sell
-100
Closed -$1.8K – 9660
2023
Q3
$1.8K Buy
+100
New +$1.97K ﹤0.01% 7827
2023
Q1
– Sell
-247
Closed -$4.64K – 10042
2022
Q4
$4.64K Buy
247
+240
+3,429% +$4.3K ﹤0.01% 9304
2022
Q3
$0 Buy
7
+2
+40% +$37 ﹤0.01% 10696
2022
Q2
$0 Buy
+5
New +$99 ﹤0.01% 10675
2022
Q1
– Sell
-7
Closed – – 10635
2021
Q4
$0 Buy
+7
New +$181 ﹤0.01% 10515

Other funds holding MDEV

UBS Group's MDEV Position: Q3 2026 in Review

UBS Group held its First Trust Indxx Medical Devices ETF (MDEV) position steady in Q3 2026 at 19 shares worth $394. The position accounts for ﹤0.01% of the portfolio, ranked #10661.

UBS Group first reported a position in MDEV in Q4 2021 and has held it in 13 quarters since. The position peaked at $17.5K in Q3 2024. 6 funds tracked by Wall St. Rank hold MDEV as of Q3 2026.

  • UBS Group held 19 shares of First Trust Indxx Medical Devices ETF worth $394 as of Q3 2026.
  • UBS Group left its First Trust Indxx Medical Devices ETF share count unchanged in Q3 2026.
  • First Trust Indxx Medical Devices ETF made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10661 holding.
  • UBS Group first reported a position in First Trust Indxx Medical Devices ETF in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's First Trust Indxx Medical Devices ETF position peaked at $17.5K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held First Trust Indxx Medical Devices ETF as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.